ESG

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, In Vivo investigates.

Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.

Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.

In her role as Boehringer's senior vice president and global head of Development Sciences, Xiaorong He emphasizes patient-centric innovation and sustainability. She is committed to incorporating patient insights into product development and advancing eco-friendly practices within the company's R&D pipeline.  

The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.

Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.

Record attendance at the 2024 MedTech Forum in Vienna heard industry leaders voice optimism grounded in realism about future developments for Europe’s medtech industry, markets and delivery of care to patients. In Vivo filtered out 16 trends to watch.

Astellas Pharma’s chief commercial officer discusses the biopharma industry’s responsibility to drive change in health care.    

The use of Artificial intelligence, data analytics and digital technologies hold the potential to transform pharmaceutical R&D and massively improve productivity. However, to achieve game-changing impact, the right technology infrastructure is required.  

Industry is researching alternatives to PVC for medicines packaging, but content integrity must remain paramount, says Circpack consultancy’s Filipe Viera de Castro, who puts the case for companies to contribute to waste management costs.

Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.  

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.  

Addie MacGregor, at the Association of British HealthTech Industries, guides and advises an industry eager to comply but in search of direction, on matters of environmental sustainability for health care technology manufacturers.

Healthtech innovators are being asked by users and clinicians how technology solutions can increase health system efficiency and respond to concerns over staff shortages. Royal Philips’ Bert van Meurs fielded these questions at ECR 2024.

20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.

Friday, 8 March is International Women’s Day, and to celebrate, Citeline spoke to female leaders from across the medtech sector about their experiences as women, women-specific issues that technology can address, and how they can empower others to reach similar – or even greater – levels of success. Take a look at some interview snapshots below:

Health care businesses seeking to reconcile positive climate action with business growth must combine long-term thinking and short-term actions. Only then will they achieve internal and external sustainability goals, says Robert Metzke, Royal Philips’ SVP and global head of sustainability.

Royal Philips CEO Roy Jakobs used the company’s 2023 results conference to update the market on the agile operating plan 2023-2025 and US actions to address the Respironics recall. Investors’ lively interest in the recall meant that strategic themes concerning environmental sustainability and future health care dividends from artificial intelligence platforms were all but sidelined.

AstraZeneca was among the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative’s corporate net zero standard. Investment in green gas, reforestation and the associated use of AI mark the company out as a thought leader in sustainability initiatives. In this context, COP28’s renewed focus on ‘climate+health’ is well timed.